ATE200427T1 - Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs - Google Patents

Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs

Info

Publication number
ATE200427T1
ATE200427T1 AT93919965T AT93919965T ATE200427T1 AT E200427 T1 ATE200427 T1 AT E200427T1 AT 93919965 T AT93919965 T AT 93919965T AT 93919965 T AT93919965 T AT 93919965T AT E200427 T1 ATE200427 T1 AT E200427T1
Authority
AT
Austria
Prior art keywords
combination
oligonucleotide
treatment
cancer
antisense oligonucleotides
Prior art date
Application number
AT93919965T
Other languages
English (en)
Inventor
Bruno Calabretta
Thomasz Skorski
Original Assignee
Univ Temple
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25510318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE200427(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Temple, Univ Jefferson filed Critical Univ Temple
Application granted granted Critical
Publication of ATE200427T1 publication Critical patent/ATE200427T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT93919965T 1992-10-21 1993-08-10 Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs ATE200427T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96567192A 1992-10-21 1992-10-21
PCT/US1993/007541 WO1994008625A1 (en) 1992-10-21 1993-08-10 Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer

Publications (1)

Publication Number Publication Date
ATE200427T1 true ATE200427T1 (de) 2001-04-15

Family

ID=25510318

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93919965T ATE200427T1 (de) 1992-10-21 1993-08-10 Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs

Country Status (7)

Country Link
EP (1) EP0668782B1 (de)
JP (1) JPH08506087A (de)
AT (1) ATE200427T1 (de)
AU (1) AU5005093A (de)
CA (1) CA2147663A1 (de)
DE (1) DE69330137T2 (de)
WO (1) WO1994008625A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69433520T2 (de) 1993-07-10 2004-11-11 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense-nukleinsäure enthaltende pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zelltod, und zur behandlung von neoplasmen
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
CA2250923A1 (en) * 1996-03-26 1997-10-02 Gabriella Zupi Oligonucleotide treatments and compositions for human melanoma
CA2272341A1 (en) * 1996-11-21 1998-05-28 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
KR100518108B1 (ko) * 1997-05-05 2005-10-04 아벤티스 파마 도이칠란트 게엠베하 사람 Ha-ras 유전자 절편에 상보적인 변형된 안티센스 뉴클레오티드
US6417169B1 (en) 1998-04-23 2002-07-09 Genesense Technologies Inc. Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
US7087580B2 (en) 1998-04-23 2006-08-08 Genesense Technologies, Inc. Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth
AU2004200032B2 (en) * 1998-10-19 2005-05-05 Methylgene, Inc Modulation of gene expression by combination therapy
US6953783B1 (en) 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
DE69920247T2 (de) * 1998-10-19 2005-09-29 Methylgene, Inc., Saint-Laurent Veränderung der dns methyltransferase durch kombinationstherapie
EP1243289A3 (de) * 1998-10-19 2004-03-17 Methylgene, Inc. Veränderung der Genexpression durch Kombinationstherapie
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
TW202015719A (zh) 2018-06-19 2020-05-01 美商尼恩醫療公司 新抗原及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055459A (en) * 1986-06-30 1991-10-08 Board Of Regents, The University Of Texas Selective elimination of malignant cells from bone marrow by bis (acyloxy) propylphosphoramidates
WO1991004753A1 (en) * 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof

Also Published As

Publication number Publication date
EP0668782A1 (de) 1995-08-30
DE69330137T2 (de) 2001-11-15
EP0668782A4 (de) 1998-09-16
CA2147663A1 (en) 1994-04-28
AU5005093A (en) 1994-05-09
JPH08506087A (ja) 1996-07-02
DE69330137D1 (de) 2001-05-17
WO1994008625A1 (en) 1994-04-28
EP0668782B1 (de) 2001-04-11

Similar Documents

Publication Publication Date Title
DE69330137D1 (de) Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs
ATE194383T1 (de) Antisense oligonukleotide gegen die alpha- regulatorische untereinheit der camp-abhängigen protein-kinase zur behandlung von krebs
ZA200304500B (en) Method for inhibiting the expression of a target gene and medicament for treating a tumor disease.
DK1163254T3 (da) TRPM-2 antisense-behandling
EP0939621A4 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
KR950702626A (ko) 치료제로서 자체-안정화된 올리고누클레오티드(self-stabilized loigonucleotides as therapeutic agents)
EP0735046A4 (de) Oligonukleotid und kanzerostatisches mittel das dieses als aktiven inhaltstoff enthält
ES2151467T1 (es) Inhibicion de la actividad de la quinasa p38 por aril-ureas.
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
ATE221914T1 (de) Gegenläufige oligonukleotide mit hemmender wirkung auf tumorbildung
DE69819167D1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
PT1053313E (pt) Oligonucleotidos ''antisense'' optimizados complementares de sequencias de dna metiltransferase
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
BR0008788A (pt) Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase
WO1999007844A3 (en) Methods and compositions for treatment of restenosis
PT775745E (pt) Aptameros inibidores de catepsina g
DE69841858D1 (de) Medikamente für massive tumore, welche inhibitoren der expression des wilms' tumorgens enthalten
ATE465261T1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
WO1999025819A3 (de) Antisense oligonukleotide gegen tenascin zur behandlung von vitiligo
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
WO2001060998A3 (en) Small oligonucleotides with anti-tumor activity
DE10346721A1 (de) Oligonukleotide, diese enthaltende Mittel und deren Verwendung
AU3881095A (en) Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
ATE391777T1 (de) Verwendung von prohibitin-rns in krebsbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties